Meta Pixel

News and Announcements

First Graphene Limited (ASX: FGR) aims to bring independent experience with appointment of UK based Non-Executive Director

  • Published October 21, 2018 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

KEY TAKEAWAYS:

  • First Graphene Limited is pleased to announce the appointment of Mr Clive Carver as a Non-Executive Director.
  • Mr Carver will be based in the UK and the First Graphene are hoping the appointment will bring further independent experience to the company.
  • The appointment comes as the company moves for Admission to AIM.

First Graphene Limited is pleased to announce the appointment of Mr Clive Carver as a Non-Executive Director.

Mr Carver will be based in the United Kingdom.

The appointment comes as the company moves for Admission to AIM, Mr Carver will bring further independent experience.

AIM has approximately 940 companies quoted, and Allenby Capital is one of the largest nomad and brokers servicing that market.

Mr Carver was an AIM Qualified Executive for 15 years and brings a lot of experience to the company.

Mr Carver has worked for a number of UK companies including: Coopers & Lybrand, Shire Trust, Williams de Broe and finnCap.

Warwick Grigor, Chairman of First Graphene Limited, said: “He brings considerable experience in operating in the finance community in the UK, which will benefit First Graphene Limited as we move into GEIC and being admitted to AIM.”

Mr Carver is currently Chairman of Caspian Sunrise PLC, and non-executive
Chairman of appScatter Group PLC, Ascent Resources PLC, and Tax Systems PLC, all of which have their shares quoted on AIM.

 

About First Graphene Limited (ASX: FGR)

First Graphene is an advanced materials company seeking to position itself in the lowest cost quartile of global graphene suppliers. It has developed an environmentally sound and safe method of converting its supplies of ultra-high grade graphite into the lowest cost highest quality graphene, in bulk quantities.

Register Interest

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now